Close Menu

kidney disease

The firms will initially use RenalytixAI's KidneyIntelX platform to help improve outcomes for patients with chronic kidney disease and its complications. 

RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.

KidneyIntelX can be used to report risk assessment results for fast-progressing kidney disease and future kidney failure for patients with chronic kidney disease.

The firm believes the multi-part stratification project will help further commercialization of its KidneyIntelX blood-based assay for acute and chronic kidney disease. 

The San Francisco-based startup believes that its QiSant assay could help guide the use of immunosuppressive drugs and other therapies to prevent kidney transplant rejection.

The RT-qPCR test was made available last week after validation in accordance with the US Food and Drug Administration's Emergency Use Authorization guidance.

CareDx first sued Natera in April 2019, accusing the company of trying to mislead patients and clinicians about the superiority of its Prospera transplant test.

The researchers identified 240 metabolite-locus associations, including novel gene candidates for biotransformation and detoxification reactions.

The magistrate did recommend that the court dismiss two counts made against Natera with respect to trademark disparagement and unfair trade practices.

In PNAS this week: gene-edited mouse model of small cell lung cancer, cystic fibrosis carrier-related conditions, and more.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.